Debt-to-equity of Checkpoint Therapeutics, Inc. from 30 Jun 2017 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Checkpoint Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2017 to 31 Mar 2025.
  • Checkpoint Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was -313%, a 119% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Checkpoint Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 -313% -170% -119% 31 Mar 2025
Q4 2024 -159% -31% -24% 31 Dec 2024
Q3 2024 -155% -19% -14% 30 Sep 2024
Q2 2024 -143% +31% +18% 30 Jun 2024
Q1 2024 -143% +163% +53% 31 Mar 2024
Q4 2023 -128% -1630% -109% 31 Dec 2023
Q3 2023 -135% -307% -179% 30 Sep 2023
Q2 2023 -174% -256% -313% 30 Jun 2023
Q1 2023 -305% -351% -766% 31 Mar 2023
Q4 2022 1502% +1473% +5010% 31 Dec 2022
Q3 2022 172% +153% +808% 30 Sep 2022
Q2 2022 82% +65% +396% 30 Jun 2022
Q1 2022 46% +25% +125% 31 Mar 2022
Q4 2021 29% +1.8% +6.6% 31 Dec 2021
Q3 2021 19% -15% -44% 30 Sep 2021
Q2 2021 16% -38% -70% 30 Jun 2021
Q1 2021 20% -43% -68% 31 Mar 2021
Q4 2020 28% -54% -66% 31 Dec 2020
Q3 2020 34% -81% -70% 30 Sep 2020
Q2 2020 54% -25% -31% 30 Jun 2020
Q1 2020 64% +5.6% +9.6% 31 Mar 2020
Q4 2019 82% +39% +92% 31 Dec 2019
Q3 2019 115% +81% +245% 30 Sep 2019
Q2 2019 79% +49% +158% 30 Jun 2019
Q1 2019 58% +31% +116% 31 Mar 2019
Q4 2018 42% +19% +82% 31 Dec 2018
Q3 2018 33% +16% +96% 30 Sep 2018
Q2 2018 31% +17% +125% 30 Jun 2018
Q1 2018 27% 31 Mar 2018
Q4 2017 23% 31 Dec 2017
Q3 2017 17% 30 Sep 2017
Q2 2017 14% 30 Jun 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.